The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Improved Biomarkers and Clinical Outcome Measures, 2020Quantification of S129 Phosphorylated Alpha-Synuclein Using the AlphaLISA Immunoassay Platform
Study Rationale:
In Parkinson's, there remains an unmet need for biomarkers to track disease progression and efficacy of potential therapies. This team of investigators is focused on fluid-based... -
Improved Biomarkers and Clinical Outcome Measures, 2020PPMI DATIQ and SR T1w MRI Analysis
Study Rationale:
Parkinson’s disease results in functional and structural changes in the brain. Non-invasive imaging methods such as SPECT and MRI can measure these changes. The dopamine transporter... -
Target Advancement Program, 2020Gene Therapy Approach to Reduce Alpha‐synuclein Aggregation in a Model of Parkinson's
Study Rationale:
A hallmark of Parkinson’s disease is the accumulation of an abnormal form of the protein alpha-synuclein inside brain cells. The team plans to use a gene therapy approach to insert a... -
Improved Biomarkers and Clinical Outcome Measures, 2020Development of a Non-Invasive Ophthalmic Diagnostic for Parkinson’s Disease
Study Rationale:
Currently, diagnosis of Parkinson’s disease relies on extensive neurological and physical examinations. A hallmark of Parkinson's is misfolded alpha-synuclein that forms aggregates... -
Therapeutic Pipeline Program, 2020Adaptive Deep Brain Stimulation for Gait Retraining in Parkinson's Disease
Study Rationale:
Walking impairment in people with Parkinson’s disease (PD) often arises from difficulties in coordinating leg movements in response to environment changes. Continuous stimulation of... -
Alpha-Synuclein Imaging, 2020PET Imaging Probe Development for Alpha-synuclein
Study Rationale:
Alpha-synuclein is a protein that can clump to form Lewy bodies and lewy neurites, which are a hallmark of Parkinson's disease. Being able to identify these clumps in living patients...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.